The recently enacted Section 456.0301, F.S., requires the Board to approve continuing education courses for those physicians who prescribe controlled substances. The proposed new rule sets forth the entities approved by the Board to provide the ...

 

DEPARTMENT OF HEALTH

Board of Osteopathic Medicine

RULE NO.:RULE TITLE:

64B15-13.0025Requirement for Continuing Education Course on Prescribing Controlled Substances

PURPOSE AND EFFECT: The recently enacted Section 456.0301, F.S., requires the Board to approve continuing education courses for those physicians who prescribe controlled substances. The proposed new rule sets forth the entities approved by the Board to provide the prescribing controlled substances course.

SUMMARY: The proposed new rule approves the Florida Medical Association, the Florida Osteopathic Medicine Association, the Florida Academy of Family Physicians, and the Florida College of Emergency Physicians, as those entities authorized by the Board to provide the continuing education course for those physicians who prescribe controlled substances.

SUMMARY OF STATEMENT OF ESTIMATED REGULATORY COSTS AND LEGISLATIVE RATIFICATION:

The Agency has determined that this will not have an adverse impact on small business or likely increase directly or indirectly regulatory costs in excess of $200,000 in the aggregate within one year after the implementation of the rule. A SERC has not been prepared by the Agency.

The Agency has determined that the proposed rule is not expected to require legislative ratification based on the statement of estimated regulatory costs or if no SERC is required, the information expressly relied upon and described herein: During discussion of the economic impact of this rule at its Board meeting, the Board concluded that this rule change will not have any impact on licensees and their businesses or the businesses that employ them. The rule will not increase any fees, business costs, personnel costs, will not decrease profit opportunities, and will not require any specialized knowledge to comply. This change will not increase any direct or indirect regulatory costs. Hence, the Board determined that a Statement of Estimated Regulatory Costs (SERC) was not necessary and that the rule will not require ratification by the Legislature. No person or interested party submitted additional information regarding the economic impact at that time.

Any person who wishes to provide information regarding a statement of estimated regulatory costs, or provide a proposal for a lower cost regulatory alternative must do so in writing within 21 days of this notice.

RULEMAKING AUTHORITY: 456.0301(2) FS.

LAW IMPLEMENTED: 456.0301 FS.

IF REQUESTED WITHIN 21 DAYS OF THE DATE OF THIS NOTICE, A HEARING WILL BE SCHEDULED AND ANNOUNCED IN THE FAR.

THE PERSON TO BE CONTACTED REGARDING THE PROPOSED RULE IS: Kama Monroe, J.D., Executive Director, Board of Osteopathic Medicine/MQA, 4052 Bald Cypress Way, Bin # C06, Tallahassee, Florida 32399-3256.

 

THE FULL TEXT OF THE PROPOSED RULE IS:

 

64B15-13.0025 Requirement for Continuing Education Course on Prescribing Controlled Substances.

(1) Pursuant to Section 456.0301, F.S., by January 31, 2019, all physicians who are registered with the United States Drug Enforcement Agency and authorized to prescribe controlled substances must complete a 2-hour course on prescribing controlled substances.

(2) The Board approves the controlled substance prescribing courses offered by the Florida Medical Association, the Florida Osteopathic Medical Association, the Florida Academy of Family Physicians, and the Florida College of Emergency Physicians, for the purpose of meeting this continuing education requirement.  The course may be offered in a distance learning format.

(3) The 2-hour controlled substances prescribing course shall be included in the total hours required for continuing education renewal purposes. 

(4) This rule requirement is not applicable to physician assistants licensed pursuant to Section 459.022, F.S.

Rulemaking Authority 456.0301(2) FS. Law Implemented 456.0301 FS. History–New.

 

NAME OF PERSON ORIGINATING PROPOSED RULE: Board of Osteopathic Medicine

NAME OF AGENCY HEAD WHO APPROVED THE PROPOSED RULE: Board of Osteopathic Medicine

DATE PROPOSED RULE APPROVED BY AGENCY HEAD: April 10, 2018

DATE NOTICE OF PROPOSED RULE DEVELOPMENT PUBLISHED IN FAR: April 23, 2018